Compare PMVP & PETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMVP | PETS |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.5M | 61.6M |
| IPO Year | 2020 | 2003 |
| Metric | PMVP | PETS |
|---|---|---|
| Price | $1.34 | $2.29 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | ★ 428.6K | 84.4K |
| Earning Date | 05-08-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.92 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $273,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $1.57 |
| 52 Week High | $1.88 | $4.32 |
| Indicator | PMVP | PETS |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 37.54 |
| Support Level | $1.26 | N/A |
| Resistance Level | $1.50 | $2.93 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 28.21 | 30.00 |
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.